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Abstract
Acute gastroenteritis (AG) is frequently caused by infectious intestinal diseases (IID) includ-
ing food- and waterborne pathogens of public health importance. Among these pathogens,
Campylobacter spp. plays a major role. Many European countries monitor selected IIDs
within disease surveillance systems. In Switzerland, the information on IIDs is restricted to
limited surveillance data, while no data is available for AG. We conducted a qualitative
study among Swiss general practitioners (GPs) to investigate the case management of AG
and campylobacteriosis patients, the associated disease burden and the determinants lead-
ing to registration in the National Notification System for Infectious Diseases (NNSID). Inter-
views were conducted with a semi-structured questionnaire and underwent inductive
content analysis based on Grounded Theory. The questionnaire was repeatedly adapted to
capture emerging themes until the point of theoretical saturation. GPs perceived AG and
campylobacteriosis of little relevance to their daily work and public health in general.
According to GP self-estimates each consults about two cases of AG per week and diagno-
ses a median of five campylobacteriosis cases per year. A large proportion of AG cases
receives telephone consultations only and gets medical advice from the practice nurse.
Antibiotic therapy is considered useful and stool diagnostics are performed for about a fifth
of consulting AG patients. Stool diagnostics (“test”) and antibiotic therapy (“treat”) are inter-
related and follow four strategies: “Wait & See”, “Treat & See”, “Treat & Test”, and “Test &
See”. AG case management is diverse and includes different triage steps. A small propor-
tion of AG patients have stool diagnostics performed and only positive tested patients are
reported to the NNSID. As a result severe cases and cases with a history of travel abroad
are overrepresented in the NNSID. The use of multiplex PCR panels in routine diagnostics
likely leads to improved case management and higher case numbers in surveillance
systems.
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Introduction
Acute gastroenteritis (AG) is characterised by diarrhoea (watery, bloody), vomiting, fever,
abdominal pain and cramps, nausea, and dehydration that occur in different combinations and
with varying degrees of severity [1–3]. Those suffering from AG are frequently affected by
infectious intestinal diseases (IID) caused by a wide range of gastrointestinal pathogens like
viruses, bacteria and other parasites [1, 4, 5]. Food- and waterborne pathogens such as Cam-
pylobacter spp. and Salmonella spp., for example, are of particular public health concern as
they can lead to disease outbreaks in addition to causing sporadic cases [6–8]. For this reason,
many IID causing pathogens are monitored in most European Union (EU) countries and in
Switzerland [9, 10]. The Swiss National Notification System for Infectious Diseases (NNSID)
monitors a range of food- and waterborne pathogens including Campylobacter spp., Salmonella
spp., Shigella spp. and enterohaemorrhagic Escherichia coli [9]. Among these, the most fre-
quently notified IID in Switzerland is campylobacteriosis. Since 2006, a dramatic increase in
case notifications has been observed, with an all-time high of almost 8,500 notified cases in
2012 [11]. Increasing trends in case notifications were also observed in the European Union
(EU) [10] e.g. England andWales [12] or Germany [13] and in the United States of America
(US) [14]. The NNSID is the only source of routine information on IIDs among the Swiss pop-
ulation, but it does not cover syndromic surveillance of AG, nor does any other surveillance
system.
The overall aim of the NNSID is to allow for the early detection of disease outbreaks and
health threats from infectious diseases to initiate timely interventions for disease control. Addi-
tionally, the system supports a continuous assessment of existing preventive measures. Only
laboratory-confirmed cases of notifiable IIDs are reported to the NNSID. Reported case data
include the patient’s personal data (name or initials, address or place of residence, sex, age), the
applied diagnostics, the diagnosing laboratory and the physician in charge [9]. However, except
for enterohaemorrhagic E. coli, the NNSID does not collect associated clinical information
such as onset of disease, signs and symptoms, progression of disease, case management, hospi-
talisations, risk exposures or risk factors for IIDs [9]. In addition to insufficient knowledge on
the clinical presentation of IIDs, the actual burden of IIDs and AG at the primary care level
and the population level are unknown. To assess the disease burden from laboratory-based sur-
veillance data at both levels, it is crucial to know the patients’ health care seeking behaviour
and the physicians’ case management including diagnostic practices. The lack of such informa-
tion considerably impedes ability of the NNSID to capture minor epidemiological trends and
interpretation of its data. The aims of this qualitative study among Swiss general practitioners
(GPs), were to investigate the case management of AG and campylobacteriosis patients, to
assess the influence of patient’s health care seeking behaviour and of GPs’ clinical decision
making on surveillance data and to collect estimates on the incidence of AG and campylobac-
teriosis at the primary care level.
Materials and Methods
Questionnaire development
We developed a semi-structured questionnaire for face-to-face interviews that was informed
by the study objectives, expert opinions and relevant literature. The questionnaire was divided
into two parts. The first part covered GPs’ perception of AG and campylobacteriosis; that is, the
perceived magnitude of the burden of AG and campylobacteriosis, incl. semi-quantitative esti-
mates, relevance to public health, the clinical presentation (signs and symptoms) in daily prac-
tice, patients’ health care seeking behaviour (motives and processes), and the patients’ profile
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as it relates to risk behaviours and risk groups. The second part, Case management, focused on
the case management of AG and campylobacteriosis by evaluating diagnostic practices and
treatment approaches (incl. influencing factors and logic behind the action) and reasons for
related decisions, like referral to a specialist or hospitalisation.
Interviewer training and pilot testing of questionnaire
Pilot and study interviews were conducted by three female social scientists (SF, MZ and SH)
and one male epidemiologist (PJB), between May and August 2013. The interviewers received
multiple trainings in qualitative interviewing techniques from a senior medical anthropologist
(JMR). Pilot testing of the questionnaire consisted of a preliminary interview with a key infor-
mant (senior GP), followed by five test interviews in German (four) and French (one). After
the pilot, the questionnaire was re-structured accommodating the common procedure during
the medical consultation with a patient with AG. The pilot indicated that the variety of deter-
minants and approaches for symptomatic treatment are rather limited. Therefore, the ques-
tionnaire rather focused on examining the complex determinants and approaches for
antibiotic therapy.
Recruitment of GPs and interview procedure
GPs who had managed campylobacteriosis patients in a previous case-control study [15] but
were otherwise not actively engaged, were invited for an interview for the purpose of the cur-
rent study. In addition to those 146 German-speaking and 29 French-speaking GPs of the case-
control study [15] we purposely recruited six French-speaking GPs for the study to better rep-
resent the French-speaking area of Switzerland. GPs were invited with an information letter
sent by postal mail. After the anticipated receipt of the information letter, GPs were contacted
by telephone and the study and study objectives were described. Verbal informed consent was
obtained and an appointment for the interview arranged. The interview was conducted at a
place of the GP’s choice, which was usually in his or her own practice. Interviews generally
lasted for 20–40 minutes and were tape recorded and transcribed.
Data analysis
Data analysis followed the principles of inductive content analysis as required by Grounded
Theory and was performed with Weft-QDA software (http://pressure.to/qda/). Upon comple-
tion, interviews were immediately transcribed and iteratively analysed, while data collection
was ongoing. This approach allowed us (i) to capture emerging themes that could be included
in subsequent interviews, (ii) to refine the question guide and (iii) to evaluate the saturation
process. Codes for data analysis were continuously developed and assigned to GPs’ narratives.
All interviews were coded by a senior medical anthropologist (JMR). Theoretical saturation of
themes and factors was eventually reached and study results were discussed at length by the
research team. Semi-quantitative estimates of the perceived magnitude of AG and campylobac-
teriosis and the rates for requesting faecal specimens are given as the reported median and
range.
Ethics statement
The work presented in this article and the previous case-control study [15] formed a project
mandated by the Swiss Federal Government studying the epidemic increase of human Cam-
pylobacter spp. infections in Switzerland. Over the last decade notification rates for campylo-
bacteriosis had not only steadily increased between 2005 and 2012 but also weekly notification
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rates peaked annually at the turn of the year. In 2011/2012 weekly notifications increased
extraordinarily twofold compared to the previous and following weeks [11]. In concert with
the general epidemiological trend this situation was categorised as an epidemic threat by the
Federal Government. In response the Federal Office of Public Health (FOPH) commissioned
the project for the winter 2012/2013 enforcing the Swiss Epidemics Act (SR 818.101 EpG).
Projects conducted under the Epidemics Act do not require ethical approval. Hence, we did
not seek approval from an ethical committee for the study but conducted the study in line with
the Declaration of Helsinki. Participating GPs provided verbal informed consent. They
received an information letter of the FOPH and were subsequently contacted by telephone.
During the telephone conversation interviewers explained again the purpose of the study and
repeated the content of the information letter. GP’s were subsequently formally asked to partic-
ipate and their response check marked on the consent form. We did not obtain written
informed consent as the interviews focused solely on GPs’ professional views about the subject
matter and not on any personal aspects or data of individual patients. The GPs’ personal data
were anonymised and they did not receive any financial compensation for their participation.
Results
Characteristics of participating GPs
In total, 69 GPs participated in the study (51 German-speaking and 18 French-speaking). The
participation rate among GPs from the previous case-control study was 36.0% (63/175). Of the
study participants, 13 (18.8%) were female and 56 (81.2%) were male. The majority (62) of
interviewed GPs had specialised in general internal medicine, while five specialised in paediat-
rics, one in anaesthesia and one in urology. The latter two also provided primary health care.
The median professional experience of GPs was 23 years (range: 3–39 years) and the median
number of patients consulted per GP per week (as estimated by the GPs) was 138 (range: 32–
300). Slightly more than half of the interviewed GPs (38/69) worked at a practice located in a
semi-urban community, and practices located in urban and rural communities accounted for
30.4% (21/69) and 14.5% (10/69) of the sample.
Perception of acute gastroenteritis and campylobacteriosis
Nearly all interviewed GPs considered AG in Switzerland to be of little relevance for the
patient, uncommon in daily practice and of minor public health importance in Switzerland
(Table 1). In contrast, GPs highlighted that AG plays an important role in travel medicine and
patients with a travel history. Interviewed GPs estimated observing a median of 2 cases of AG
per week (range: 0–10 cases per week) and a median of 5 (range: 0–52) laboratory-confirmed
cases of campylobacteriosis each year. GPs highlighted that the real number of campylobacter-
iosis cases is higher than that indicated by laboratory-confirmed cases due to patients’ health
care seeking behaviour (not all AG patients contact a GP) and GPs’ testing behaviour (not all
AG cases are tested). The general perception was that, Campylobacter spp. has surpassed Sal-
monella spp. as the primary cause of bacterial diarrhoea in Switzerland, compared to the 1990s.
Campylobacteriosis cases occur in waves or phases throughout the year and usually peak dur-
ing the summer months and between December and January. GPs explicitly linked the summer
peak to barbequing and the winter peak to traditional consumption of meat fondue (Table 1).
GPs agreed on the basic signs of bacterial AG, particularly for campylobacteriosis: symp-
toms like abdominal pains and cramps or fever appear abruptly and the patient feels and pres-
ents as very ill (Table 2). Nausea and vomiting were also mentioned but occur less frequently.
Some GPs also mentioned pain in the limbs and headache. Campylobacteriosis was seen as a
self-limiting disease, easy to treat, and generally not dangerous for peoples’ health (Table 1).
Acute Gastroenteritis and Campylobacteriosis in Primary Care
PLOS ONE | DOI:10.1371/journal.pone.0161650 September 7, 2016 4 / 17
However it can lead to a severe, painful and disturbing health condition that prevents people
from working (Table 2). GPs recognised the importance of AG and campylobacteriosis for vul-
nerable patients such as infants, the elderly, or individuals suffering from co-morbidities. Cam-
pylobacteriosis can affect anyone, independently of age, sex or socio-economic status.
However, young adults and middle-aged people appear to be affected more frequently than the
rest of the population, and especially more frequently than vulnerable groups. The perceived
risk factors for contracting campylobacteriosis mentioned were: handling and eating raw or
Table 2. Clinical presentation and risk groups for campylobacteriosis.
Participant Quotes
PJB17 “It’s [symptoms of campylobacteriosis] for sure relatively fast appearing diarrhoea, watery
diarrhoea, nausea, frequently fever. So they are really doing badly for a few days.”
MZ13 “They [campylobacteriosis cases] mostly have fever. But it is mostly not very high.Whereby
this also occurs for viral infections. . . .The patients have also a bad general condition. Blood
[in stool] I don't see so often. (. . .) The patients simply feel bad.When one only has a gastro-
intestinal flu, one doesn't feel fit. One also has to run to the toilet all the time. But somehow,
people with campylobacter really look very bad. (. . .)They are very pale and almost collapse.”
MZ01 “Campylobacteriosis goes across all the social strata, all generations, across everything.”
PJB21 “No, it [the risk group] is less children,mostly age groups from 20–25 to 60–65 years, this
middle group. Less so children and older people.”
PJB16 “Until they [the patients] start to improve a little after three to four days, until they are healthier
again it goes approximately one week. Then they return to work, except if they have a physical
work, then, it might need a little bit longer. But people working in the office or students can go
back to work after a week–still a little impaired, not completely normal yet. Then it gradually
improves.”
PJB14 “Independent of the stool test, the patient is anyway ill for three to five days and can’t go for
work. For patients working in the food sector,maybe even ten to fourteen days. The
employers don’t really like it because it is a long time.”
PJB05 “Another reason [for treating with antibiotics] is the importance of the working position of the
patient. Some really need to go to work, others do not. Some ask for it [antibiotics].”
doi:10.1371/journal.pone.0161650.t002
Table 1. Perception and burden of acute gastroenteritis and campylobacteriosis in Swiss primary
care.
Participant Quotes
SFY12 “I have the impression that they [campylobacteriosis and AG] are not such a public health
problem. Because I do, if I have them, if I discover them. . .I treat them. I don’t have the
impression that they. . .in any case for me. . .they are not a problem for me.”
MZ20 “(. . .) Diarrheal diseases only become problematic when there is an electrolyte and fluid
imbalance.Most at risk are children. (. . .) But all in all, it is not a problem. Diarrheal diseases
are generally self-limiting.”
MZ20 “So, first of all, I do not diagnose every campylobacter case or every bacterial diarrhoeal case.
I only conduct targeted testing. I do not do routine testing in the case of diarrhoea. This means
that I certainly miss some of the cases.”
SF02 “Indeed. Before, the main problem was Salmonella. I have rarely seen Shigella. Very rarely.
Nowadays, campylobacter is more common.”
SF01 “In summer, it can be [observed] during the barbeque season, it [barbeque] is a fostering
element.”
MZ01 “One can see this after every festivity day. So after Christmas, people show up with
campylobacter infections. This is due to the poultry. Fondue chinoise [meat fondue] is
stretched out with poultry.”
“After the fondue chinoise season there are increasing campylobacter infections, yes.”
PJB16 “Mostly it is fondue chinoise or barbeques. That is the classic. Nowadays it is rarely eggs or
sauces compared to earlier times, but fondue chinoise is really classic.
doi:10.1371/journal.pone.0161650.t001
Acute Gastroenteritis and Campylobacteriosis in Primary Care
PLOS ONE | DOI:10.1371/journal.pone.0161650 September 7, 2016 5 / 17
undercooked poultry, travelling and eating “unsafe” food, eating out in canteens or restaurants,
barbecuing, consuming meat fondue with poultry or ready-to-eat salads and working in the
food sector. Campylobacteriosis patients are generally unable to work for several days to more
than one week (Table 2). The patient’s general condition is the main criterion for sickness certi-
fication and duration of sick leave. Other medical factors linked to occupation (physical or
nonphysical activities; activities that can put others at risk) or social factors (like pressure by
the employer or the patients themselves) also play a role.
Health care seeking behaviour and medical encounters at the primary
care level
GPs reported on patients’ individual health care seeking behaviour. Individuals affected by AG
consult their GP within several hours to days after the onset of symptoms. Factors accounting
for prompt or delayed patient consultation included perceived severity, pain and distress, past
experiences, attitude towards coping with disease, health insurance deductible or the need for a
medical certificate. Up to 60% of all AG-related enquiries lead to telephone consultations only,
without a face-to-face consultation at the practice. Thus, practice nurses play a key role in eval-
uating the severity of disease, filtering patients for consultations at the practice and providing
appropriate medical advice on the telephone. Several physical (e.g. severity), psychosocial (e.g.
anxiety, mutual trust), and situational (e.g. GPs’ workloads) factors can favour either telephone
or face-to-face consultations. After the first consultation and with appropriate measures taken,
most GPs either schedule a follow-up appointment (usually by phone but sometimes at the
medical practice) or ask patients to call if the symptoms do not improve. The follow-up serves
as a means for evaluating the course of disease and for establishing further actions if needed.
GPs’ workloads can be an obstacle to routine follow-up. Medical treatment is either concluded
passively, i.e. patients do not contact the GP again, or actively at a follow-up consultation.
Diagnostic and treatment approaches
Routine consultation of an AG patient starts with history taking, including assessment of
potential risk exposures followed by a clinical examination and point-of-care diagnostics (e.g.
C-reactive protein (CRP) level). Faecal specimens for diagnostic purposes (mainly stool-cul-
tures for Campylobacter spp., Salmonella spp. and Shigella spp.) are requested for a median of
18% (5–60%) of AG patients depending on the general condition, fever, blood in faeces, ele-
vated CRP level e.g.>100 mg/l, prolonged disease duration, relevant co-morbidities, patient’s
occupation and a positive history of ingesting risky food or of travel (Table 3).
Symptomatic treatment of AG, including antimotility drugs and oral rehydration therapy
for simple cases or intravenous rehydration therapy for severe cases, is very common (Table 4).
Antibiotic therapy plays only a secondary role due to the self-limiting nature of most AG cases.
Nevertheless, antibiotic therapy is considered useful but prescribed cautiously. Its indication
depends on disease severity, general condition, fever, inflammation parameters, occupation
and partially on stool diagnostic results (Table 5). GPs mostly prescribe ciprofloxacin and to a
lesser extent erythromycin or specific classes of antibiotics, depending on the stool diagnostic
result. Most GPs were concerned about potential antibiotic resistance of gastrointestinal bacte-
ria. However, only some remembered experiencing this problem in their medical practice
(Table 5). GPs were aware that frequent prescription of antibiotics is positively associated with
the occurrence of antibiotic resistance. However, many also consider antibiotic therapies as
very helpful for individual treatment, even if not medically indicated, to shorten disease dura-
tion or to ameliorate symptoms, for example.
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The interplay of stool diagnostics and antibiotic therapy
Initiating stool diagnostics (“Test”) is interrelated with antibiotic therapy (“Treat”) and follows
four distinct approaches to acting and reacting in specific medical, social and physical situa-
tions (Table 6). GPs can lean towards “Treat & See”, “Treat & Test” or “Test & See”, and some
can “Wait & See” longer than others. Few respondents openly refused an individual approach
or adhered to one of these approaches only. The approaches “Wait & See” and “Treat & Test”
appeared to be preferred.
Wait & See. This approach seems to be the standard starting point for most AG episodes.
It is based on the principle that symptoms of AG including campylobacteriosis disappear after
two to five days. It is mostly applied when the episode is recent and mild, or if the patient is in
good general condition. Practice nurses evaluate the patient by telephone and decide if there is
Table 4. Symptomatic treatment approaches for AG cases among Swiss GPs.
Participant Quotes
MZ11 “So primarily, I administer probiotics. At first, I focus on nutritional establishment and
[recommend] the intake of fluids with light meals and without any dairy products for two, three
days. Like this, one manages the patient slowly. This is standard for me.”
PJB18 “There is the “solution of thirds”. (. . .) one third orange juice, one third black tea and one third
mineral water, heavily sugared. (. . .) It contains everything, potassium in the orange juice,
bicarbonate in the mineral water and you have fluid and sugar. (. . .) [it] is a cheap electrolyte
solution.”
PJB02 “And then only if. . .someone has 12 stools per day, I also give antidiarrhoeals. This is
something that relieves the symptoms. But otherwise, in the first 3 days, cleaning of the
intestine belongs to the body’s self-healing processes."
PJB06 “So what I mean, what I sometimes do, I give someone an infusion.When somebody is prone
to collapsing and has low blood pressure with nothing risky otherwise. Then we do an infusion
here or at home. This I indeed like to do, I like to offer this.”
PJB21 “They do essentially get better and the fever decreases faster if one gives an infusion and puts
the fluid balance a little back in order.”
doi:10.1371/journal.pone.0161650.t004
Table 3. Diagnostic approaches for AG cases among Swiss GPs.
Participant Quotes
MZ23 “For each patient, I first make an anamnesis. I ask him since when has he had it.When did it
start? Have you eaten something special? Have you done something special? Have you been
abroad? Just the anamnesis. After this, the first impression of the patient.When there is
massive diarrhoea, you can see that the patient is suffering. An important symptom is fever.
Febrile diarrhoea has to be looked at differently. (. . .) Then I usually take CRP and blood status.
Harmless diarrhoea has mostly a CRP of 20 to 40. But campylobacter have often 100, 120.
Sometimes, they also have a leucocytosis. And when I have a suspicion, I request a stool
examination.”
MZ19 “Fever, bad general condition and when the patient himself says that he feels bad. Then I do a
blood test, so CRP and leucocytes. I only check stool bacteriology when the values are clearly
increased.”
PJB06 “An anamnesis revealing a risk situation. I say it like this, did he have a risk situation, did he eat
eggs, or poultry products or mozzarella or such products somewhere, so farmer products (. . .)
or does he have fever?”
MZ16 “In fact, there are two reasons for which one generally makes a stool examination: If the
patient really feels ill and miserable. (. . .) As a general rule, I then give Imodium.When the
patient has taken it correctly, and it doesn't work, then I might do a stool test. Then there is a
second group: Patients who were abroad. For these patients, it is possible that I primarily do a
stool test. (. . .) Then there is a third group, where I primarily do a stool examination.When the
patients come from an old people's home and one knows that there are already several people
who fell ill.”
doi:10.1371/journal.pone.0161650.t003
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a need for a consultation or if the patient should wait out the disease’s progression. Diet, rehy-
dration and symptomatic treatment recommendations are provided at this stage.
Treat & See. Few GPs reported treating AG with antibiotics without requesting a faecal
specimen. The underlying logic is that there is no need to know the exact cause of AG for a suc-
cessful treatment, particularly if there is indication of a bacterial infection, such as an elevated
CRP level. Other reasons were: the costs of stool diagnostics, wish to reduce the duration of suf-
fering and infeasibility of requesting a faecal specimen (if the patient has to travel or the epi-
sode occurs just before the weekend, for example). The approach is a pragmatic one, focused
on patients’ wellbeing and against the perceived norm for cautious use of antibiotics.
Treat & Test. Antibiotic therapy starts before knowing the stool diagnostic result but after
faecal specimen collection. It can then be modified upon receiving diagnostic results. This
approach implies that empirical treatment usually works and that stool diagnostics are helpful
for the post-diagnostic adaptation of antibiotic therapy. GPs’ responses indicate the need to
start antibiotic therapy immediately due to social (e.g. the patient has to work) and medical
considerations (e.g. bad general condition). Reasons for applying this approach include the
possibility of redirecting treatment if indicated, and considering public health aspects (e.g. if
the patient works in the food sector or in health care).
Test & See. This approach implies that antibiotic therapy only starts if indicated and after
knowing the stool diagnostic result. However, antibiotics are only indicated if bacterial patho-
gens are identified and symptoms persist or the patient’s general condition deteriorates. Then
the approach transforms to “Test and Treat” and the patient receives the pathogen-specific
antibiotic therapy. GP’s applying this approach seek to avoid unnecessary and empirical ‘best-
guess’ antibiotic therapies.
Referrals
Generally, GPs manage AG patients themselves at their practices. Complex cases of AG are
referred to a specialist (gastroenterologist, specialist for infectious diseases, specialist in tropical
Table 5. Prescription of antibiotic therapy for AG cases and the perception of antibiotic resistance.
Participant Quotes
MZ23 “If somebody feels really sick and has a high fever, I may give him antibiotics quicker than
recommended. (. . .) But on the other hand. . .if somebody has a fever of 39 degrees for two
days and diarrhoea, you don't leave him to wait for another two, three days.With these cases,
I am relatively easy in giving antibiotics.”
PJB17 “The indication of antibiotics is generally not due to the test result campylobacter, but rather
due to the symptomatology”
MZ18 Interviewer: “When do you give antibiotics?”
“If there is extremely high fever and there are extremely high inflammation values, a CRP of
100 or higher.”
PJB14 “If I don’t know the pathogen yet, I empirically give ciprofloxacin.”
Interviewer: “And after you get the test result?”
“If it is Campylobacter jejuni, I change to a macrolide”
MZ15 “In fact, I almost always treat with ciprofloxacin. I attended a tropical course. There I have
heard that resistances are building slowly and that erythromycin products would be better.
But up to now, I have always had good experiences with ciprofloxacin.”
PJB02 “The resistance problem is known. Often there is a quinolone-resistance and then macrolides
have to be used. It is only a matter of time until resistances also appear there.”
PJB18 “Yes I had one single case that did not react to it [ciprofloxacin]. . .with campylobacter. There, I
had to do a second culture with an antibiotic resistance profile. Then it worked, indeed with
azithromycin and not with ciprofloxacin.”
doi:10.1371/journal.pone.0161650.t005
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Table 6. Diagnostic and antibiotic therapy approaches among Swiss GPs.
Approach Quotes
Wait & See PJB08: “Waiting doesn’t mean omitting.Watchful waiting as it is called. It is a pleasant fact
that, in general, a lot of problems that we are confronted with in general medicine are self-
limiting. For this reason, I do not have to make a big effort concerning diagnostics. One
decides based on the evidence (observing the course of the disease) and says: ‘Come again
in two days’.Mostly they have to come again for a medical certificate. Or I tell the patient to
report within a certain period if it doesn’t improve.”
MZ18: “Basically, one goes ahead step by step. First, one observes. One waits. One leaves it
open. One only does a stool culture when diarrhoea persists. Not for every patient.”
Interviewer: “So the self-healing tendency plays a role?”
MZ18: “Exactly. One waits, often for one week or so. But when the pains are extreme or it
takes longer, then we take a stool culture.”
Treat & See MZ17: “I am convinced that for 99% of the cases, we don't know the disease agent.We treat
with a broad spectrum antibiotic. I cannot make a throat smear for every patient with sore
throat (. . .). I think this is not the objective of a general practitioner.”
Interviewer: “So in the end you treat blindly. So, independent of a test result.”
MZ18: “Yes, exactly. This is in our science not unusual. One applies a broad spectrum
antibiotic. (. . .) For a lung infection, for example, you of course do not know whether a patient
has this or that bacterium. This is of no interest to me in the general practice. And in general,
it does not help the patient either. If you make a culture then you have the result maybe next
Wednesday or Thursday.When you must send the sample you have to consider that the
patient has pains and inflammation values for the next four, five days.What is the examination




MZ03: “And then there is such a thing. . . there is such a cookbook rule, if there is bloody
diarrhoea, or febrile diarrhoea. After doing stool bacteriology I give mostly ciprofloxacin. I say:
“You go home first, then you fill the container, and then you swallow these tablets”. And this
has shown quite good results. (. . .) And I say he should not take the tablets beforehand,
otherwise we do not know what it is and we have no diagnosis, if it does not get better. (. . .)
And I know it [test result] within four days. “Usually you [the patient] get better. But if you do
not feel better, we know which bug it is."
MZ15: “Mostly, one also does a CRP, in order to determine whether it is a bacterium or a
virus. (. . .) Depending on the result of the blood examination, I give him [the patient] a tube to
take home. I always say then that it costs a lot of money. If you feel better, we don't need to
send it. One has to treat anyway before one has the result. (. . .) it is practically always blind
treatment. It is rare that the laboratory calls and we have not yet treated. It is then rather a
confirmation that something is there. I, in fact, almost always treat with ciprofloxacin. (. . .)
When I have the impression that the patient does not necessarily want to know it, I take the
stool sample and I start treatment.When he gets better, we don't send it.”
MZ19: “When a patient comes with this psycho-social pressure, for example he has to work,
then you do give him antibiotics. Then I don't wait until I receive the results. I treat
immediately.”
Test & See PJB03: “When the patient says he hasn’t improved at all, the test result is there,maybe
against expectation. . .of campylobacter, and he says: ‘I don’t get better at all’, he has still
stomach cramps, diarrhoea and so on, then I treat him”
Interviewer: “So it might take some time until you get the test result.What is the influence of
this in your treatment?”
PJB23: “Generally none. In the first phase, the treatment is independent of the stool sample.”
Interviewer: “In the first phase.What do you do then with a positive result?”
PJB23: “Let’s say it is salmonella or campylobacter positive, it doesn’t mean that they get
ciprofloxacin. It simply means that one keeps an eye on them. I look how fast they recover
and follow-up after a week, checking inflammation indicators.”
Interviewer: “So a positive test result doesn’t always indicate an antibiotic use or so?”
PJB23: “No. (. . .) A young healthy person can overcome these diseases without antibiotics,
they are not necessary. Second, there is a risk that we will have more chronic carriers if we
give antibiotics. For salmonella this is known, they recover faster but they remain longer
carriers, really for a long time and this is what I want to avoid.”
doi:10.1371/journal.pone.0161650.t006
Acute Gastroenteritis and Campylobacteriosis in Primary Care
PLOS ONE | DOI:10.1371/journal.pone.0161650 September 7, 2016 9 / 17
and travel medicine) or a hospital. Reasons for referring a patient to a specialist include the
development of persistent or chronic gastroenteritis (e.g. diarrhoea persists several weeks, pro-
longed blood in faeces) or no response to the usual treatments. A specialist in travel medicine
is specifically approached if gastrointestinal problems persist after travelling abroad. Hospitali-
sation of AG patients is rather uncommon. Hospital referrals occur in case of bad general con-
dition, severe dehydration, fear of sepsis, suspicion of diverticulitis or appendicitis or if
vulnerable patients suffer from severe AG. They also occur in cases where patients cannot man-
age at home due to lack of social support (e.g. elderly people living alone) or travel (e.g. tourists
staying in a hotel).
Discussion
A qualitative study among 69 GPs in Switzerland on the clinical presentation and case manage-
ment of acute gastroenteritis and campylobacteriosis showed that GPs see around two patients
with AG per week and a median of 5 campylobacteriosis cases per year. However, AG patients
can also treat themselves at home, sometimes with medical advice from the practice nurse.
Campylobacteriosis and AG are perceived as having little relevance for general public health,
daily clinical practice and the average patient. Case management in the form of antibiotic ther-
apy and stool diagnostics follows four approaches: “Wait & See”, “Treat & See”, “Treat & Test”
or “Test & See”. GPs request faecal specimens for stool diagnostics from 18% of AG patients
and prefer empirical antibiotic therapy before stool diagnostic results are available over result-
based antibiotic therapy.
The burden of acute gastroenteritis and campylobacteriosis
GPs generally observe that, among causes of IIDs, Campylobacter spp. has surpassed Salmo-
nella spp. in the last 20 years. This is confirmed by the trends of campylobacteriosis and salmo-
nellosis case numbers reported to the NNSID [11]. Similar trends in notification rates were
observed in the EU [10] e.g. Wales [16] whereas in the US the incidence of Salmonella spp.
remained higher than for Campylobacter spp. [14, 17]. NNSID data also support GPs’ impres-
sions that young adults and middle-aged people are more frequently affected [11]. More preva-
lent exposure risks among these groups, such as traveling abroad, eating out and preparing
food themselves, as stated by GPs, could be responsible for increased case numbers. However,
data to support this assumption are not yet available for Switzerland.
The described seasonality of campylobacteriosis cases is reflected in the NNSID data [11].
Two distinct peaks of campylobacteriosis, one during summer months and one shorter peak
over the festive season in December and January, lead to more primary care attendance. The
summer peak of campylobacteriosis case notifications is observable throughout Europe [10].
The winter peak has been described in detail for Switzerland and Germany and is also observ-
able in European notification data [10, 11, 13]. GPs associated the frequent consumption of
meat fondue over the festive season in winter with increased campylobacteriosis case numbers.
Indeed, meat fondue consumption was found to be the major risk factor for the winter peak of
campylobacteriosis in Switzerland, as it is tradition to consume it at Christmas and New Year
times [15]. The association of the summer peak with the barbeque season is plausible as barbe-
quing meat provides many occasions for undercooking and re- and cross-contamination [18].
Studies in Switzerland [19] and Germany [20] showed higher Campylobacter spp. contamina-
tion rates of chicken meat during summer months. Additional drivers for infection could also
be more frequent recreational water activities or travels in summer, both risk factors that have
been previously described for campylobacteriosis [18, 21–23]. GPs also observed that consulta-
tions due to AG occur in a clustered manner, with alternating case-free weeks and then several
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cases occurring in a single week. This might be due to small, local epidemics of viral IIDs. Swit-
zerland does not have routine syndromic surveillance of AG, which would allow investigations
of temporal and seasonal AG trends. This would be desirable, as other European countries
such as France have had positive experiences with routine syndromic surveillance of AG [24].
The influence of patients’ health care seeking behaviour on NNSID case
numbers
Many AG affected individuals do not contact a GP at all or only get advice by telephone,
depending on their health care seeking behaviour. GPs are aware that this leads to an underes-
timation of the IID burden at the primary care level and has—together with case management
approaches—an influence on NNSID case numbers. This has already been described for other
disease surveillance systems [5, 25, 26]. However, patients suffering from a bacterial gastroin-
testinal infection appear to be more likely to consult a GP than patients with a viral gastrointes-
tinal infection [5, 27]. In the Netherlands, national GP guidelines recommend telephone
consultations by practice nurses to deal with simple AG cases to reduce the number of consul-
tations and stool diagnostics [28]. In Switzerland, the active promotion of telephone consulta-
tions for patients with mild AG could help to reduce health care expenditures, which are
among the highest in the world [29]. According to study GPs, severely affected patients often
directly consult the emergency department of a hospital, whereas the average AG case is dealt
with at the practice and is rarely referred to a specialist or hospital. This is comparable with
other findings reporting 8.5% of GPs hospitalising an AG patient during the seven days preced-
ing the interview [30]. However, hospitalised AG patients suffering from an IID are likely to
undergo intensive diagnostics and, hence, will not be missed by the NNSID if diagnosed with a
notifiable disease.
The influence of diagnostic approaches on NNSID case numbers
The GPs’ self-estimated proportion of requesting faecal specimens for 18% of patients is com-
parable to other studies where rates vary between 4.3% and 50% [25, 28, 31–33]. Individual
rates differed strongly among the GPs interviewed. The observed heterogeneity seems to be
rather common and has also been observed among English GPs [31]. It is likely related to GPs’
individually perceived usefulness of stool diagnostic results for case management and the
patient populations they serve. This highlights the need to systematically estimate the faecal
specimen testing rate to assess the disease burden of notifiable IIDs at the primary care level
from NNSID case numbers.
The determinants for requesting a faecal specimen, as found by this study, are similar to
those found in other studies [28, 30–32, 34–36] and are consistent with published recommen-
dations on the clinical management of AG cases [4, 37]. Additionally, our study showed that
factors related to the health system (e.g. health insurance deductible or duration of stool diag-
nostics) also influence the decision to perform stool diagnostics. An important determinant for
performing stool diagnostics was the patient’s CRP level. An elevated CRP level is considered
indicative of a bacterial infection, making distinct stool diagnostics more likely. Arguments for
this criterion were the limited treatment possibilities for viral causes of AG and the need to
know the bacterial cause for targeted antibiotic therapy. Requesting a faecal specimen based on
a positive travel history, as observed in our study, may not always be appropriate as stool diag-
nostics are not recommended for watery or traveller’s diarrhoea due to the low yield of recog-
nising pathogenic bacteria (e.g. enterotoxigenic E. coli) in the sample [37]. In accordance with
others [32, 34], we observed that mainly severely affected patients or patients with a history of
travelling abroad undergo stool diagnostics in Switzerland, likely leading to a high proportion
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of severe and imported cases in the NNSID. Imported and domestic cases cannot be distin-
guished in the NNSID for most IIDs as laboratory reports do not include any information on
exposure. Hence, the possible overrepresentation of imported cases should be considered when
interpreting NNSID data as they are of less relevance for assessing national disease transmis-
sion and interventions. To improve the interpretation of NNSID data it would be advisable to
include patients’ recent travel history on case notifications to differentiate between imported
and domestic cases, similarly to other European countries [10]. The preference of severe cases
for stool diagnostics also explains the perceived high severity of disease by notified cases (7 on
a rating scale from 1 = not severe, to 10 = very severe) and the high antibiotic prescription rate
(61.6%) found in our case-control study on determinants of campylobacteriosis in Switzerland
[15].
When the study was conducted, the first diagnostic laboratories had introduced multiplex
polymerase chain reaction (PCR) panels for IIDs in routine diagnostics. Up until then, the rou-
tine stool diagnostics applied to AG patients were stool-cultures for Campylobacter spp., Sal-
monella spp. and Shigella spp. [38]. Only a few of the interviewed GPs had already deliberately
ordered stool diagnostics with this new diagnostic tool. Multiplex PCR panels will likely affect
case numbers in the NNSID if they are routinely deployed by Swiss GPs. They have a higher
detection rate of IIDs in faecal specimens compared to conventional methods due to a higher
sensitivity and the wide range of IIDs tested simultaneously [39–41]. Greater sensitivity will
likely lead to increased case numbers of the routinely tested and notifiable IIDs (Campylobacter
spp., Salmonella spp. and Shigella spp.) within the NNSID. Similarly, stool diagnostics for
other specific notifiable IIDs, e.g. enterohaemorrhagic E. coli, were mainly requested for AG
patients with a certain suspicion such as blood in faeces. More tests will be conducted for these
IIDs because faecal specimens investigated by multiplex PCR panels are tested for the same
range of IIDs independent of the suspected cause which could lead to the detection of more
cases.
“Treat & See” and “Treat & Test” for targeted antibiotic therapies
The GPs in our study considered stool diagnostics and antibiotic therapy useful for managing
AG cases. The “Wait & See” approach, including symptomatic treatment, is the approach
applied most often to AG case management among Swiss GPs. This is in line with published
case management guidelines for simple AG cases [1, 4, 37, 38]. From a public health perspec-
tive, the “Treat & See” and “Treat & Test” approaches are questionable as both can lead to
untargeted antibiotic therapies. Similar to the “Wait & See” approach, the “Treat & See”
approach additionally contributes to the underreporting of IID cases in the NNSID.
Studies have shown that a large proportion of faecal specimens from AG patients do not
identify viral pathogens and, hence, disease is likely not caused by bacteria [42–45]. The afore-
mentioned approaches bear a high probability of incorrectly treating those patients with antibi-
otics. In the era of increasing antibiotic resistance among gastrointestinal bacterial pathogens,
untargeted antibiotic therapy should be avoided. Additionally, antibiotic therapy needs to be
carefully considered for its potentially counter-productive effects for bacterial infections such
as Escherichia coli O157:H7, for example [46, 47]. Timely antibiotic therapy is desirable to
reduce disease duration and to increase the wellbeing of the patient in cases of severe AG (e.g.
with febrile dysentery with an indication of a bacterial cause such as an elevated CRP level or
based on food history) [4, 36, 37].
A major reason for applying the “Treat & See” and “Treat & Test” approaches is the per-
ceived long duration until culture-based stool diagnostic results are available. Therefore, fast
molecular diagnostics for IIDs such as multiplex PCR panels would enable the physician to
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initiate timely and targeted antibiotic therapy and are desirable [36, 39]. When these are widely
deployed, “Test & See” could become the preferred approach to AG case management over
“Wait & See”. The fast availability of diagnostic results will also permit a shift to “Test and
Treat”, including a specific and timely treatment approach based on stool diagnostic results.
GPs in our study were prone to change their treatment approach based on the stool diagnostic
results. However, immediate antibiotic therapy will remain the therapy of choice for severely
affected patients to assure the wellbeing of the patient.
Swiss surveillance data shows that Campylobacter spp. is the most frequent bacterial cause
of IIDs [11]. But around 50% of tested Campylobacter spp. isolates from humans are resistant
to fluoroquinolones according to Swiss study and surveillance data [48, 49]. Therefore, the pre-
scription of ciprofloxacin (fluoroquinolone) for AG cases with a suspected bacterial cause, as
mentioned by interviewed GPs, is questionable. Azithromycin (macrolide) would be the drug
of choice for treating campylobacteriosis and is also appropriate for treating salmonellosis and
shigellosis [4, 37]. A similar level of resistance of Campylobacter spp. to fluoroquinolones is
observed in EU countries, but varies considerably between countries. As a result, the European
Food Safety Authority and the European Centre for Disease Prevention and Control no longer
consider fluoroquinolones appropriate for routine empirical treatment of human campylobac-
teriosis [50]. In summary, empirical antibiotic therapy for the treatment of AG patients should
be avoided whenever possible and macrolides (e.g. azithromycin or erythromycin) are recom-
mended for empirical treatment if it is indicated for the wellbeing of the patient.
Discussion of research approach
A wide range of GPs was accessible through the previously conducted case-control study [15]
and provided an ideal and unique opportunity to assess the case management of AG and campy-
lobacteriosis patients and the associated disease burden at the primary care level. A qualitative
research approach was chosen due to the lack of information on AG and campylobacteriosis at
the primary care level in Switzerland and the unknown willingness of GPs to participate. This
allowed researchers to collect information on all aspects of interest nearly independent of the par-
ticipation rate, but limited the possibilities for quantifying some of the results. Semi-quantitative
estimates on the disease burden by GPs allowed a first assessment of the unknown disease burden
at the primary care level. Such estimates of disease burden should be interpreted with caution as
they are influenced by several factors. The progression of the interview, the time point of the
interview in regard to disease seasonality or the GP’s importance alluded to the disease can lead
to over- or underestimation. The large sample of 69 GPs from the German- and French-speaking
parts of Switzerland increased the geographical and paradigmatic variation represented, leading
to an improved saturation of investigated themes. Additionally, interviewers followed-up on vari-
ous topics with different levels of detail during the interviews due to different backgrounds of
interviewers, resulting in even wider variation and fast theoretical saturation. We lack interviews
with GPs from the Italian-speaking part of Switzerland but we assume that–due to the minor dif-
ferences between French- and German-speaking GPs–differences in case management and dis-
ease burden would only slightly differ from our study results. It might appear that the study
generated only general knowledge, but it is the first and largest study to date providing a compre-
hensive overview of the applied case management, disease burden and determinants leading to
disease notification in Switzerland.
Conclusions
The health care seeking behaviour of AG patients leading to primary care attendance, and GPs’
varying case management approaches including triage steps and stool diagnostic frequency
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need to be taken into account when interpreting NNSID data. Patients severely affected by AG
or who travelled abroad are more frequently seeking care and are hence, overrepresented
among campylobacteriosis cases notified in the NNSID. As a result, the NNSID monitors the
epidemiological situation of notifiable IIDs of more severe disease expressions rather than the
entire spectrum of notifiable IID suffering in the Swiss population. The current transition from
routine culture-based stool diagnostics to routine multiplex PCR panels in diagnostic laborato-
ries will likely counter act such a skewed epidemiological data situation. This expectation is
mainly driven by the higher sensitivity of these molecular diagnostics and by a possible increase
in the number of stool diagnostics conducted due to faster availability of diagnostic results.
Therefore, the anticipated increase in case numbers will not necessarily reflect an epidemiologi-
cal trend in the Swiss population and should be considered when communicating NNSID data
to stakeholders. Knowledge on which diagnostic methods are available and actually applied is
important for public health authorities to accurately interpret NNSID data, particularly during
the transition period. Consequently, further research should be conducted on the impact of
routine multiplex PCR panels on the composition and number of cases registered in the
NNSID and possible changes in case management including antibiotic therapies.
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